{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:43:13Z","timestamp":1760186593873,"version":"build-2065373602"},"reference-count":113,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.hoc.2014.06.007","type":"journal-article","created":{"date-parts":[[2014,7,22]],"date-time":"2014-07-22T03:15:29Z","timestamp":1405998929000},"page":"791-813","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Diagnosis and Risk Stratification in Multiple Myeloma"],"prefix":"10.1016","volume":"28","author":[{"given":"Niels W.C.J.","family":"van de Donk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.hoc.2014.06.007_bib1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"issue":"33","key":"10.1016\/j.hoc.2014.06.007_bib2","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.1200\/JCO.2010.30.8791","article-title":"Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group","volume":"28","author":"Dimopoulos","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2014.06.007_bib3","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3324\/haematol.2012.075051","article-title":"Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials","volume":"98","author":"Bringhen","year":"2013","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.hoc.2014.06.007_bib4","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.hoc.2014.06.007_bib5","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/leu.2009.89","article-title":"International Myeloma Working Group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.hoc.2014.06.007_bib6","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1158\/1078-0432.CCR-10-1843","article-title":"Genomics in multiple myeloma","volume":"17","author":"Munshi","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.hoc.2014.06.007_bib7","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/leu.2012.282","article-title":"Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project","volume":"27","author":"vet-Loiseau","year":"2013","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.hoc.2014.06.007_bib8","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.3324\/haematol.2009.016436","article-title":"Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation","volume":"95","author":"Neben","year":"2010","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.hoc.2014.06.007_bib9","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome","volume":"109","author":"Avet-Loiseau","year":"2007","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2014.06.007_bib10","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1038\/sj.leu.2404304","article-title":"Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma","volume":"20","author":"Chiecchio","year":"2006","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.hoc.2014.06.007_bib11","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1182\/blood.V122.21.529.529","article-title":"Co-existent hyperdiploidy does not abrogate the poor prognosis associated with adverse cytogenetics in myeloma","volume":"122","author":"Melchor","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2014.06.007_bib12","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/leu.2011.204","article-title":"A\u00a0novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial","volume":"26","author":"Boyd","year":"2012","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.hoc.2014.06.007_bib13","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1182\/blood-2002-03-0749","article-title":"Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy","volume":"100","author":"Moreau","year":"2002","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2014.06.007_bib14","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1182\/blood-2005-04-1411","article-title":"Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy","volume":"106","author":"Gertz","year":"2005","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2014.06.007_bib15","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1182\/blood-2002-10-3017","article-title":"Clinical and biologic implications of recurrent genomic aberrations in myeloma","volume":"101","author":"Fonseca","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2014.06.007_bib16","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1182\/blood-2011-09-379164","article-title":"Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p","volume":"119","author":"Neben","year":"2012","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.hoc.2014.06.007_bib17","doi-asserted-by":"crossref","first-page":"7069","DOI":"10.1200\/JCO.2005.17.129","article-title":"Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance","volume":"23","author":"Jaksic","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"30","key":"10.1016\/j.hoc.2014.06.007_bib18","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1200\/JCO.2010.28.3945","article-title":"Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p)","volume":"28","author":"vet-Loiseau","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"10.1016\/j.hoc.2014.06.007_bib19","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1200\/JCO.2012.46.2598","article-title":"Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myelome experience","volume":"31","author":"vet-Loiseau","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2014.06.007_bib20","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.hoc.2014.06.007_bib21","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2141.2007.06639.x","article-title":"Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3","volume":"138","author":"Barlogie","year":"2007","journal-title":"Br J Haematol"},{"issue":"9758","key":"10.1016\/j.hoc.2014.06.007_bib22","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.hoc.2014.06.007_bib23","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/GMMG-HD4 trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2014.06.007_bib24","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1182\/blood-2010-07-295105","article-title":"Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?","volume":"117","author":"vet-Loiseau","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2014.06.007_bib25","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood.V99.10.3735","article-title":"Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients","volume":"99","author":"Fonseca","year":"2002","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2014.06.007_bib26","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1182\/blood.V95.6.1925","article-title":"Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization","volume":"95","author":"Zojer","year":"2000","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2014.06.007_bib27","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1182\/blood.V97.6.1566","article-title":"Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy","volume":"97","author":"Facon","year":"2001","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.hoc.2014.06.007_bib28","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1182\/blood-2010-04-279596","article-title":"A\u00a0compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value","volume":"116","author":"Walker","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2014.06.007_bib29","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013","volume":"88","author":"Mikhael","year":"2013","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"10.1016\/j.hoc.2014.06.007_bib30","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1365-2141.2009.07864.x","article-title":"TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3","volume":"147","author":"Shaughnessy","year":"2009","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.hoc.2014.06.007_bib31","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/bmt.2009.107","article-title":"1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma","volume":"45","author":"Chang","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"27","key":"10.1016\/j.hoc.2014.06.007_bib32","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1200\/JCO.2008.20.6136","article-title":"Prognostic significance of copy-number alterations in multiple myeloma","volume":"27","author":"Avet-Loiseau","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2014.06.007_bib33","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ccr.2006.03.019","article-title":"High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients","volume":"9","author":"Carrasco","year":"2006","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.hoc.2014.06.007_bib34","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1158\/0008-5472.CAN-06-4046","article-title":"Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling","volume":"67","author":"Chng","year":"2007","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.hoc.2014.06.007_bib35","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1182\/blood-2011-11-390658","article-title":"Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.hoc.2014.06.007_bib36","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1182\/blood-2009-12-261032","article-title":"Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients","volume":"116","author":"Broyl","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2014.06.007_bib37","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2014.06.007_bib38","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2005-01-0034","article-title":"Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma","volume":"106","author":"Bergsagel","year":"2005","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2014.06.007_bib39","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A\u00a0validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.hoc.2014.06.007_bib40","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1182\/blood-2010-12-328252","article-title":"Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3","volume":"118","author":"Shaughnessy","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2014.06.007_bib41","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1038\/leu.2012.127","article-title":"A\u00a0gene expression signature for high-risk multiple myeloma","volume":"26","author":"Kuiper","year":"2012","journal-title":"Leukemia"},{"issue":"29","key":"10.1016\/j.hoc.2014.06.007_bib42","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1200\/JCO.2007.13.8545","article-title":"Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myelome","volume":"26","author":"Decaux","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2014.06.007_bib43","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1158\/1078-0432.CCR-09-2831","article-title":"Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome","volume":"16","author":"Dickens","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.hoc.2014.06.007_bib44","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1182\/blood-2011-03-341933","article-title":"Reduction in plasma cell proliferation after initial therapy in newly diagnosed multiple myeloma measures treatment response and predicts improved survival","volume":"118","author":"Larsen","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2014.06.007_bib45","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/j.ajpath.2012.07.020","article-title":"Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005<65y trials","volume":"181","author":"Paiva","year":"2012","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.hoc.2014.06.007_bib46","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/01.coc.0000045810.91816.41","article-title":"Ki-67 proliferation index: correlation with prognostic parameters and outcome in multiple myeloma","volume":"27","author":"Alexandrakis","year":"2004","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2014.06.007_bib47","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3324\/haematol.2010.030296","article-title":"Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma","volume":"96","author":"Hose","year":"2011","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.hoc.2014.06.007_bib48","doi-asserted-by":"crossref","first-page":"521","DOI":"10.7326\/0003-4819-110-7-521","article-title":"High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma","volume":"110","author":"Barlogie","year":"1989","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.hoc.2014.06.007_bib49","doi-asserted-by":"crossref","first-page":"931","DOI":"10.7326\/0003-4819-115-12-931","article-title":"High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma","volume":"115","author":"Dimopoulos","year":"1991","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.hoc.2014.06.007_bib50","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/1096-8652(200010)65:2<132::AID-AJH7>3.0.CO;2-L","article-title":"High serum lactate dehydrogenase level predicts short survival after vincristine-doxorubicin-dexamethasone (VAD) salvage for refractory multiple myeloma","volume":"65","author":"Suguro","year":"2000","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.hoc.2014.06.007_bib51","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1600-0609.2005.00532.x","article-title":"Multiple myeloma in elderly patients: prognostic factors and outcome","volume":"75","author":"Anagnostopoulos","year":"2005","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.hoc.2014.06.007_bib52","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1600-0609.2010.01466.x","article-title":"High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents","volume":"85","author":"Terpos","year":"2010","journal-title":"Eur J Haematol"},{"issue":"12","key":"10.1016\/j.hoc.2014.06.007_bib53","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.3109\/10428194.2011.597906","article-title":"Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens","volume":"52","author":"Eleftherakis-Papapiakovou","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.hoc.2014.06.007_bib54","first-page":"798","article-title":"Unusual myelomas: a review of IgD and IgE variants","volume":"27","author":"Pandey","year":"2013","journal-title":"Oncology (Williston Park)"},{"issue":"2","key":"10.1016\/j.hoc.2014.06.007_bib55","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/annonc\/mdq393","article-title":"Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients","volume":"22","author":"Kim","year":"2011","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2014.06.007_bib56","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.3324\/haematol.2012.065698","article-title":"Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents","volume":"97","author":"Usmani","year":"2012","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.hoc.2014.06.007_bib57","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.3324\/haematol.2012.078519","article-title":"Extramedullary involvement in multiple myeloma","volume":"97","author":"Blade","year":"2012","journal-title":"Haematologica"},{"issue":"23","key":"10.1016\/j.hoc.2014.06.007_bib58","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","article-title":"Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation","volume":"118","author":"Zamagni","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2014.06.007_bib59","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","article-title":"F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma","volume":"114","author":"Bartel","year":"2009","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2014.06.007_bib60","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1182\/blood-2012-05-408682","article-title":"How I treat plasma cell leukemia","volume":"120","author":"van de Donk","year":"2012","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2014.06.007_bib61","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1200\/JCO.2006.08.5803","article-title":"Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications","volume":"25","author":"Walker","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2014.06.007_bib62","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.3324\/haematol.2012.065359","article-title":"Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma","volume":"97","author":"Hillengass","year":"2012","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.hoc.2014.06.007_bib63","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1093\/annonc\/mdi362","article-title":"Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma","volume":"16","author":"Moulopoulos","year":"2005","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2014.06.007_bib64","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1182\/blood-2012-08-451690","article-title":"Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3","volume":"121","author":"Usmani","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2014.06.007_bib65","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3324\/haematol.2012.066555","article-title":"Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data","volume":"98","author":"Waheed","year":"2013","journal-title":"Haematologica"},{"issue":"15","key":"10.1016\/j.hoc.2014.06.007_bib66","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2014.06.007_bib67","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/leu.2008.402","article-title":"Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)","volume":"23","author":"Kastritis","year":"2009","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.hoc.2014.06.007_bib68","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1182\/blood.V91.7.2501","article-title":"Plasmablastic morphology\u2013an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group","volume":"91","author":"Greipp","year":"1998","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.hoc.2014.06.007_bib69","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood.V122.21.687.687","article-title":"A\u00a0simple score, based on geriatric assessment, improves prediction of survival, and risk of serious adverse events in elderly newly diagnosed multiple myeloma patients","volume":"122","author":"Bringhen","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2014.06.007_bib70","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","article-title":"International Myeloma Working Group Consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation","volume":"32","author":"Palumbo","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1016\/j.hoc.2014.06.007_bib71","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1182\/blood.V122.21.760.760","article-title":"Long-term (10 years or more) survivors of multiple myeloma: a population-based analysis of the US National Cancer Data Base","volume":"122","author":"Al-Hamadani","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2014.06.007_bib72","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3324\/haematol.2013.087585","article-title":"Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a Subgroup Analysis From the HOVON-65\/GMMG-HD4 Trial","volume":"99","author":"Scheid","year":"2014","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.hoc.2014.06.007_bib73","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.leukres.2010.04.024","article-title":"Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents","volume":"34","author":"Roussou","year":"2010","journal-title":"Leuk Res"},{"issue":"2","key":"10.1016\/j.hoc.2014.06.007_bib74","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/leu.2012.182","article-title":"The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma","volume":"27","author":"Dimopoulos","year":"2013","journal-title":"Leukemia"},{"issue":"36","key":"10.1016\/j.hoc.2014.06.007_bib75","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1200\/JCO.2009.22.2232","article-title":"VMP (bortezomib, melphalan, and prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study","volume":"27","author":"Dimopoulos","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"30","key":"10.1016\/j.hoc.2014.06.007_bib76","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1200\/JCO.2010.28.1238","article-title":"Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study","volume":"28","author":"Ludwig","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"10.1016\/j.hoc.2014.06.007_bib77","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1002\/cncr.25139","article-title":"The efficacy and safety of lenalidomide plus dexamethasone in relapsed and\/or refractory multiple myeloma patients with impaired renal function","volume":"116","author":"Dimopoulos","year":"2010","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.hoc.2014.06.007_bib78","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood-2010-09-307645","article-title":"Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients","volume":"117","author":"Gay","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2014.06.007_bib79","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3324\/haematol.11534","article-title":"Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma","volume":"92","author":"van de Velde","year":"2007","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.hoc.2014.06.007_bib80","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1182\/blood-2009-03-211953","article-title":"Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols","volume":"114","author":"Hoering","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2014.06.007_bib81","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1182\/blood-2011-01-332320","article-title":"Long-term prognostic significance of response in multiple myeloma after stem cell transplantation","volume":"118","author":"Martinez-Lopez","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2014.06.007_bib82","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/bmt.2008.180","article-title":"Impact of early relapse after auto-SCT for multiple myeloma","volume":"42","author":"Kumar","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.hoc.2014.06.007_bib83","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood-2011-07-370460","article-title":"High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma","volume":"119","author":"Paiva","year":"2012","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.hoc.2014.06.007_bib84","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1200\/JCO.2012.46.2119","article-title":"Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study","volume":"31","author":"Rawstron","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2014.06.007_bib85","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1200\/JCO.2010.33.1967","article-title":"Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma","volume":"29","author":"Paiva","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2014.06.007_bib86","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1200\/JCO.2009.23.7172","article-title":"Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma","volume":"28","author":"Ladetto","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2014.06.007_bib87","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.bbmt.2012.10.008","article-title":"Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma","volume":"19","author":"Kr\u00f6ger","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.hoc.2014.06.007_bib88","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A\u00a0clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"issue":"18","key":"10.1016\/j.hoc.2014.06.007_bib89","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1182\/blood-2010-10-300970","article-title":"Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2","volume":"117","author":"Munshi","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2014.06.007_bib90","doi-asserted-by":"crossref","first-page":"532","DOI":"10.4065\/mcp.2009.0677","article-title":"Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapies","volume":"85","author":"Kapoor","year":"2010","journal-title":"Mayo Clin Proc"},{"issue":"21","key":"10.1016\/j.hoc.2014.06.007_bib91","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood.V122.21.767.767","article-title":"Double vs single autologous stem cell transplantation after bortezomib-based induction regimens for multiple myeloma: an integrated analysis of patient-level data from Phase European III Studies","volume":"122","author":"Salwender","year":"2013","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2014.06.007_bib92","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/leu.2009.174","article-title":"International Myeloma Working Group molecular classification of multiple myeloma: spotlight review","volume":"23","author":"Fonseca","year":"2009","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.hoc.2014.06.007_bib93","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.3324\/haematol.2011.056176","article-title":"Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders","volume":"97","author":"Ross","year":"2012","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.hoc.2014.06.007_bib94","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/leu.2013.247","article-title":"IMWG consensus on risk stratification in multiple myeloma","volume":"28","author":"Chng","year":"2014","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.hoc.2014.06.007_bib95","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/bjh.12394","article-title":"Improved risk stratification in myeloma using a microRNA-based classifier","volume":"162","author":"Wu","year":"2013","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.hoc.2014.06.007_bib96","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1038\/leu.2011.147","article-title":"MicroRNA signatures characterize multiple myeloma patients","volume":"25","author":"Corthals","year":"2011","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.hoc.2014.06.007_bib97","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1182\/blood-2012-05-432203","article-title":"Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma","volume":"121","author":"Bergsagel","year":"2013","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2014.06.007_bib98","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.3324\/haematol.2011.042713","article-title":"Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire","volume":"96","author":"Roos-Weil","year":"2011","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.hoc.2014.06.007_bib99","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/leu.2011.214","article-title":"Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma","volume":"26","author":"van de Donk","year":"2012","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.hoc.2014.06.007_bib100","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1517\/14656566.2013.805746","article-title":"New developments in the management and treatment of newly diagnosed and relapsed\/refractory multiple myeloma patients","volume":"14","author":"van de Donk","year":"2013","journal-title":"Expert Opin Pharmacother"},{"issue":"12","key":"10.1016\/j.hoc.2014.06.007_bib101","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1182\/blood-2011-06-297853","article-title":"Approach to the treatment of multiple myeloma: a clash of philosophies","volume":"118","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2014.06.007_bib102","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood-2012-06-438101","article-title":"High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance","volume":"121","author":"Broyl","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2014.06.007_bib103","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.leukres.2013.08.015","article-title":"The clinical significance of cereblon expression in multiple myeloma","volume":"38","author":"Schuster","year":"2014","journal-title":"Leuk Res"},{"issue":"8","key":"10.1016\/j.hoc.2014.06.007_bib104","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1182\/blood-2006-09-044974","article-title":"Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib","volume":"109","author":"Mulligan","year":"2007","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.hoc.2014.06.007_bib105","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood.V122.21.285.285","article-title":"Prolonged survival and improved response rates with ARRY-520 in relapsed\/refractory multiple myeloma (RRMM) patients with low \u03b1-1 acid glycoprotein (AAG) levels: results from a Phase 2 Study","volume":"122","author":"Shah","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.06.007_bib106","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2741\/4202","article-title":"Lorvotuzumab mertansine: antibody-drug-conjugate for CD56(+) multiple myeloma","volume":"19","author":"Berdeja","year":"2014","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"8","key":"10.1016\/j.hoc.2014.06.007_bib107","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1158\/2159-8290.CD-13-0014","article-title":"Targeting the BRAF V600E mutation in multiple myeloma","volume":"3","author":"Andrulis","year":"2013","journal-title":"Cancer Discov"},{"issue":"21","key":"10.1016\/j.hoc.2014.06.007_bib108","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1182\/blood.V122.21.755.755","article-title":"Pilot study to evaluate the prevalence of actionable oncogenic mutations in patients with relapsed refractory multiple myeloma","volume":"122","author":"Gonen","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2014.06.007_bib109","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S1470-2045(10)70206-0","article-title":"Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65\/GMMG-HD4 trial","volume":"11","author":"Broyl","year":"2010","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2014.06.007_bib110","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2008-04-147884","article-title":"Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis","volume":"112","author":"Sarasquete","year":"2008","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.hoc.2014.06.007_bib111","doi-asserted-by":"crossref","first-page":"4924","DOI":"10.1182\/blood-2008-02-140434","article-title":"Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping","volume":"112","author":"Johnson","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2014.06.007_bib112","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.hoc.2014.06.007_bib113","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma","volume":"23","author":"Kyle","year":"2009","journal-title":"Leukemia"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858814000811?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858814000811?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:02:33Z","timestamp":1760184153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858814000811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":113,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0889858814000811"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2014.06.007","relation":{},"ISSN":["0889-8588"],"issn-type":[{"type":"print","value":"0889-8588"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosis and Risk Stratification in Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2014.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}